Full-Time

Associate Director

Clinical Quality Assurance and Compliance

Posted on 9/23/2025

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

No salary listed

Remote in USA

Remote

Northeast preferred

Category
QA & Testing (1)
Required Skills
Google Cloud Platform
Requirements
  • A bachelor’s degree in a scientific discipline or biotechnology field
  • A minimum of 6 years relevant GCP experience in pharma/biotech company, working within quality systems and regulated GCP/ICH environments
  • Experience leading and facilitating inspection readiness activities and hosting FDA and other regulatory agency inspections
  • Experience managing internal and external audits
  • Strong understanding of GCPs, FDA, and ICH regulatory standards/guidance documents
  • Extensive knowledge of risk-based quality systems approaches, with a focus on ICH E6 R2 GCP principles
  • Experience using Veeva Quality Vault
  • Ideally will also have experience in facilitating/participating in remote audits and quality activities; able to travel to Clinical sites/vendors as required; Travel Requirement expected to be up to 25%
Responsibilities
  • Build the Clinical Quality Assurance and Compliance function and infrastructure to support Invivyd pipeline and other compliance-related activities
  • Participate on cross-functional team meetings as the Clinical Quality Assurance Subject Matter Expert (SME)
  • Create, implement, and maintain efficient, phase-appropriate, and compliant GCP, GLP, and GVP systems and policies/procedures
  • Partner with other stakeholders across the organization to develop and maintain cross-functional SOPs, policies, procedures, and systems/activities consistent with corporate objectives
  • Assist the Clinical Development organization in establishing procedures to support a risk-based approach to oversight of clinical trials using principles of quality by design and quality risk management
  • Proactively identify potential quality issues/discrepancies and work with Management to effectively resolve in a compliant and timely manner
  • Provide Clinical Quality Support for Clinical Vendor/CRO oversight
  • Represent Invivyd Clinical Quality on Sponsor/CRO/Site project calls and provide updates to Management
  • Provide Clinical Quality support for critical quality issues, protocol deviations, investigations, root causes, and CAPAs
  • Develop a risk-based audit program to conduct effective audits of internal processes, investigator sites, and vendors that support development activities
  • Establish clinical quality procedures and tools in support of audit and compliance activities
  • Collaborate with key stakeholders in development and implementation of internal and external GCP audit plans
  • Assist in the development, implementation, and maintenance of training and compliance programs
  • Directly responsible for GCP, GLP, and GVP training and conduct of associated training sessions as required
  • Partner with stakeholders on maintenance and implementation of other training across the organization (i.e., CMC Quality Assurance, IT, HR, Finance, Corporate Compliance, Medical Affairs) to ensure full compliance
  • Proactively provide key stakeholders with intelligence on changes and updates to ICH and GCP regulations and assess impact on Invivyd systems and practices
  • Lead strategy and activities in support of GCP, GLP, and GVP health authority inspections
  • Review regulatory clinical and nonclinical documents such as protocols, clinical study reports, IBs, ICFs, etc. and check for consistency and compliance with relevant regulations, standards, and best practices
Desired Qualifications
  • Experience in facilitating/participating in remote audits and quality activities; able to travel to Clinical sites/vendors as required; Travel Requirement expected to be up to 25%

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • DECLARATION Phase 3 trial fully enrolled with mid-2026 data readout for VYD2311 launch.
  • PEMGARDA revenue grew 31% sequentially in Q4 2025, validating antibody prophylaxis market demand.
  • Pipeline expansion into measles, RSV, and long COVID addresses multiple high-need viral indications.

What critics are saying

  • Low COVID community attack rates force 30% trial expansion, risking 6-9 month data delay.
  • Stock price below $1 triggers Nasdaq delisting risk, halting institutional investment and capital access.
  • Competing extended half-life COVID antibodies from AstraZeneca and Regeneron capture immunocompromised market share.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering for evolved immunity.
  • Targets immunocompromised populations underserved by traditional vaccines with monoclonal antibody prophylaxis.
  • FDA Fast Track designation for VYD2311 accelerates COVID-19 prevention development versus competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.

INACTIVE